{"id":"https://openalex.org/W4394286992","doi":"https://doi.org/10.6084/m9.figshare.3503387","title":"Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of ATG5","display_name":"Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of ATG5","publication_year":2016,"publication_date":"2016-07-27","ids":{"openalex":"https://openalex.org/W4394286992","doi":"https://doi.org/10.6084/m9.figshare.3503387"},"language":"en","primary_location":{"id":"pmh:oai:figshare.com:article/3503387","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Metastatic_risk_and_resistance_to_BRAF_inhibitors_in_melanoma_defined_by_selective_allelic_loss_of_i_ATG5_i_/3503387","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"volume":null,"type":"dataset","is_traditional":false,"indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://figshare.com/articles/dataset/Metastatic_risk_and_resistance_to_BRAF_inhibitors_in_melanoma_defined_by_selective_allelic_loss_of_i_ATG5_i_/3503387","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Garc\u00eda-Fern\u00e1ndez, Mar\u00eda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Garc\u00eda-Fern\u00e1ndez, Mar\u00eda","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061315439","display_name":"Panagiotis Karras","orcid":"https://orcid.org/0000-0002-7642-0875","observed_orcids":["https://orcid.org/0000-0002-7642-0875"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karras, Panagiotis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089239625","display_name":"Agnieszka Ch\u0119ci\u0144ska","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Checinska, Agnieszka","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069295566","display_name":"Estela Ca\u00f1\u00f3n","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ca\u00f1\u00f3n, Estela","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040449658","display_name":"Guadalupe T. Calvo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Calvo, Guadalupe T.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053487646","display_name":"Gonzalo Gom\u00e9z-L\u00f3pez","orcid":"https://orcid.org/0000-0002-4146-0551","observed_orcids":["https://orcid.org/0000-0002-4146-0551"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G\u00f3mez-L\u00f3pez, Gonzalo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016920135","display_name":"Metehan Cifdaloz","orcid":"https://orcid.org/0000-0003-1153-7535","observed_orcids":["https://orcid.org/0000-0003-1153-7535"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cifdaloz, Metehan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071207437","display_name":"Angel Colmenar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Colmenar, Angel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040912403","display_name":"Luis Espinosa\u2010Hevia","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Espinosa-Hevia, Luis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087040073","display_name":"David Olmeda","orcid":"https://orcid.org/0000-0001-5513-5621","observed_orcids":["https://orcid.org/0000-0001-5513-5621"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Olmeda, David","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5024409549","display_name":"Mar\u00eda S. Soengas","orcid":"https://orcid.org/0000-0003-0612-6299","observed_orcids":["https://orcid.org/0000-0003-0612-6299"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Soengas, Mar\u00eda S.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10587","display_name":"Autophagy in Disease and Therapy","score":0.5303000211715698,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10587","display_name":"Autophagy in Disease and Therapy","score":0.5303000211715698,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.40230000019073486,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.010599999688565731,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.921999990940094},{"id":"https://openalex.org/keywords/atg5","display_name":"ATG5","score":0.9649999737739563},{"id":"https://openalex.org/keywords/autophagy","display_name":"autophagy","score":0.8029999732971191},{"id":"https://openalex.org/keywords/loss-of-heterozygosity","display_name":"loss of heterozygosity","score":0.7260000109672546},{"id":"https://openalex.org/keywords/metastasis","display_name":"metastasis","score":0.7329999804496765},{"id":"https://openalex.org/keywords/braf-inhibitor-resistance","display_name":"BRAF inhibitor resistance","score":0.8610000014305115},{"id":"https://openalex.org/keywords/dabrafenib","display_name":"dabrafenib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/copy-number-variation","display_name":"copy number variation","score":0.7870000004768372},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.8199999928474426},{"id":"https://openalex.org/keywords/melanocyte-lineage","display_name":"melanocyte lineage","score":0.6830000281333923},{"id":"https://openalex.org/keywords/lysosome-trafficking","display_name":"lysosomal trafficking","score":0.6359999775886536},{"id":"https://openalex.org/keywords/autophagy-related-genes","display_name":"autophagy-related genes","score":0.6980000138282776}],"concepts":[{"id":"https://openalex.org/C180754005","wikidata":"https://www.wikidata.org/wiki/Q80726","display_name":"Allele","level":3,"score":0.6514562368392944},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6005793809890747},{"id":"https://openalex.org/C57473165","wikidata":"https://www.wikidata.org/wiki/Q7315604","display_name":"Resistance (ecology)","level":2,"score":0.5362861156463623},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.4177204966545105},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4011889398097992},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.39328742027282715},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.37872248888015747},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.373754620552063},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.2147785723209381},{"id":"https://openalex.org/C6557445","wikidata":"https://www.wikidata.org/wiki/Q173113","display_name":"Agronomy","level":1,"score":0.06000262498855591}],"mesh":[],"locations_count":3,"locations":[{"id":"pmh:oai:figshare.com:article/3503387","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Metastatic_risk_and_resistance_to_BRAF_inhibitors_in_melanoma_defined_by_selective_allelic_loss_of_i_ATG5_i_/3503387","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.3503387","doi":"https://doi.org/10.6084/m9.figshare.3503387","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.3503387","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.3503387.v1","doi":"https://doi.org/10.6084/m9.figshare.3503387.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.3503387.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"}],"best_oa_location":{"id":"pmh:oai:figshare.com:article/3503387","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Metastatic_risk_and_resistance_to_BRAF_inhibitors_in_melanoma_defined_by_selective_allelic_loss_of_i_ATG5_i_/3503387","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1964972868","https://openalex.org/W2059388879","https://openalex.org/W2800339942","https://openalex.org/W2010656553","https://openalex.org/W2751682201","https://openalex.org/W2535993440","https://openalex.org/W4361834413","https://openalex.org/W3133662879","https://openalex.org/W3187423241","https://openalex.org/W2475377084"],"abstract_inverted_index":{"Melanoma":[0],"is":[1,33,53],"a":[2,8,36,69,75,103,119,174,186],"paradigm":[3],"of":[4,43,59,72,77,86,96,106,137,159,191,207,213,218],"aggressive":[5],"tumors":[6],"with":[7],"complex":[9],"and":[10,61,83,127,164],"heterogeneous":[11],"genetic":[12],"background.":[13],"Still,":[14],"melanoma":[15,51,162,192],"cells":[16],"frequently":[17],"retain":[18],"developmental":[19],"traits":[20],"that":[21,153],"trace":[22],"back":[23],"to":[24,50,63,168],"lineage":[25,38],"specification":[26],"programs.":[27],"In":[28],"particular,":[29],"lysosome-associated":[30],"vesicular":[31],"trafficking":[32],"emerging":[34],"as":[35,48,102,185,204],"melanoma-enriched":[37],"dependency.":[39],"However,":[40],"the":[41,57,166,215],"contribution":[42],"other":[44,124,131,145],"lysosomal":[45],"functions":[46],"such":[47],"autophagy":[49,89,125,208],"progression":[52],"unclear,":[54],"particularly":[55],"in":[56,118,130,177,201],"context":[58],"metastasis":[60,163],"resistance":[62],"targeted":[64,169],"therapy.":[65],"Here":[66],"we":[67],"mined":[68],"broad":[70],"spectrum":[71],"cancers":[73],"for":[74,144],"meta-analysis":[76],"mRNA":[78],"expression,":[79],"copy":[80,139],"number":[81,140],"variation":[82],"prognostic":[84,135],"value":[85],"13":[87],"core":[88],"genes.":[90,148],"This":[91,134],"strategy":[92],"identified":[93],"heterozygous":[94,154],"loss":[95,112],"ATG5":[97,111,138,184],"at":[98],"chromosome":[99],"band":[100],"6q21":[101,146],"distinctive":[104],"feature":[105],"advanced":[107],"melanomas.":[108,220],"Importantly,":[109],"partial":[110,205],"predicted":[113],"poor":[114],"overall":[115],"patient":[116],"survival":[117],"manner":[120],"not":[121,128,142,156],"shared":[122],"by":[123,172],"factors":[126],"recapitulated":[129],"tumor":[132],"types.":[133],"relevance":[136],"was":[141],"evident":[143],"neighboring":[147],"Melanocyte-specific":[149],"mouse":[150],"models":[151],"confirmed":[152],"(but":[155],"homozygous)":[157],"deletion":[158],"Atg5":[160],"enhanced":[161],"compromised":[165],"response":[167],"therapy":[170],"(exemplified":[171],"dabrafenib,":[173],"BRAF":[175],"inhibitor":[176],"clinical":[178],"use).":[179],"Collectively,":[180],"our":[181],"results":[182],"support":[183],"therapeutically":[187],"relevant":[188],"dose-dependent":[189],"rheostat":[190],"progression.":[193],"Moreover,":[194],"these":[195],"data":[196],"have":[197],"important":[198],"translational":[199],"implications":[200],"drug":[202],"design,":[203],"blockade":[206],"genes":[209],"may":[210],"worsen":[211],"(instead":[212],"counteracting)":[214],"malignant":[216],"behavior":[217],"metastatic":[219]},"counts_by_year":[],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2024-04-08T00:00:00"}